Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 7;9:50. doi: 10.1038/s41413-021-00173-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — AAV-Runx1 overexpression alleviates the pathological changes in growth plate cartilage. a Histological staining, including H&E, Masson, and safranin O, showing the effects of AAV-Runx1 overexpression on growth plate cartilage at 24 weeks after ACLT surgery. b μ-CT results showing changes in the thickness of growth plate cartilage in AAV-Runx1-overexpressing articular cartilage at 24 weeks after ACLT surgery. c μ-CT results showing the changes in subchondral cancellous bone in AAV-Runx1-overexpressing articular cartilage at 24 weeks after ACLT surgery. d Quantitative analysis of the thickness (width) in b in growth plate cartilage in AAV-Runx1-overexpressing mice. e Quantitative analysis of BV/TV in c in AAV-Runx1-overexpressing mice at 24 weeks after ACLT surgery. f IHC staining showing the changes in Col2a1 in the growth plate in AAV-Runx1-overexpressing articular cartilage at 24 weeks after ACLT surgery. g Immunofluorescence staining showing the changes in SOX9 in the growth plate in AAV-Runx1-overexpressing articular cartilage at 24 weeks after ACLT surgery. h Immunofluorescence staining showing the changes in ColX in the growth plate in AAV-Runx1-overexpressing articular cartilage at 24 weeks after ACLT surgery. i Immunofluorescence staining showing the changes in MMP13 in the growth plate in AAV-Runx1-overexpressing articular cartilage at 24 weeks after ACLT surgery. These results are based on at least three independent experiments (n = 3). All significance data presented in d and e are based on two-tailed Student’s t-tests